PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31753813-4 2019 Here, we report the case of a KLC1-ALK-rearranged NSCLC patient responding to crizotinib treatment and demonstrate how analysis of plasma and serum biomarkers can be used to identify the ALK fusion partner and monitor therapy over time. Crizotinib 78-88 kinesin light chain 1 Homo sapiens 30-34